FACT SHEET

Therapeutic Foresight. Trusted Results.

INC Research is a therapeutically focused global clinical research organization (CRO) providing a complete range of Phase I Phase IV clinical development services for the worlds biopharmaceutical companies. Our mission is to help our customers bring products to market to improve world health.
INC Research provides significant scale, scope and expertise to deliver innovative clinical development approaches and strategic alliances that meet the needs of our customers. In July 2011, INC Research acquired Kendle International, a leading global CRO, to create a new enviable force in global drug development outsourcing. With the addition of Kendle, INC Research is now better positioned to participate in evolving drug development outsourcing models that require broader capabilities and critical mass. The new company is also in a stronger position to drive overall quality and efficiency improvements through more innovative and forward-thinking outsourcing approaches. Customers that partner with the new INC Research will benefit from our: Global Scale and Experience. Our operations extend across six continents with experience spanning more than 100 countries. We are able to deploy more high-quality teams worldwide to handle large-scale clinical trials. Reinforced Therapeutic Expertise. INC Research and Kendle have combined their extensive therapeutic expertise to provide global therapeutic coverage in the largest areas of R&D investment, including cardiovascular, CNS, endocrine, infectious disease, oncology and respiratory. These therapeutic areas accounted for approximately two-thirds of the total U.S. drug development pipeline in 2010 (Frost & Sullivan). New Levels of Operational Excellence. With expanded global size and scale, INC Research can deliver the next generation of strategic partnerships. We have gained economies of scale to deliver clinical development programs more cost effectively. We also are evolving our proven Trusted Process methodology to include more cutting-edge methods and tools to reduce variability and increase predictability in trial outcomes across all phases of clinical development. A Commitment to Growth and Exceptional Service INC Research is committed to rapid growth in the global drug development outsourcing marketplace. The Kendle acquisition marks the ninth successful acquisition and integration for INC Research in 10 years.

INC Research Fact Sheet | July 2011

FACT SHEET

Both INC Research and Kendle share a common culture around customer-centric, high-quality service delivery. These shared values will drive our success moving forward. INC Research at a Glance Top-tier global CRO headquartered in Raleigh, North Carolina Approximately 5,000 employees across six continents with experience spanning more than 100 countries More than 6,500 studies conducted across Phase I-IV with more than 2.2 million patients enrolled Therapeutic coverage in more than two-thirds of drugs in development Industry-leading patient access and retention capabilities Customers include 43 of the worlds top 50 pharmaceutical companies Among the pioneers of the Functional Service Provider (FSP) partnership model to streamline operations and enhance efficiencies Unique combination of critical key services spanning the drug development lifecycle to ensure your projects success Experience Across All Major Therapeutic Areas INC Research has a world-class reputation for its deep therapeutic expertise across a broad range of medical conditions, as well as for special populations, such as women and pediatrics. Our therapeutic teams are among the most experienced in the industry and bring their high level of expertise and passion to every clinical trial. Our local and global therapeutic experience includes cardiovascular, CNS, endocrine, immunology, infectious disease, oncology and respiratory. Phase I to Post-Approval, We Are the Experts Phase I: INC Research is unrivaled in its ability to run successful studies at the earliest stages of a products lifecycle. We understand how important it is for you to reach an informed decision quickly and can help you determine whether your product has marketplace potential before we even begin a study. Our network of Phase I specialists includes some of the leading experts in the field. You will find they understand your goals and develop groundbreaking, customized approaches to streamline your study and make it cost effective. We conduct first-in-human studies through proof-of-concept and offer full support for Phase I studies in established compounds including bioequivalence and pharmacokinetics studies. Phase II-III: When it comes to Phase II-III studies, the INC Research approach is based on anticipating needs, communicating effectively to drive innovation and accelerating productivity to meet your critical milestones. Whether your trial is a single-dose, placebo-controlled therapeutic clinical trial, a surgical or medical device trial, a large, complex Phase IIIB study, or a smaller regional trial, INC Researchs therapeutic expertise and global capabilities ensure your success.

www.incresearch.com

INC Research Fact Sheet | July 2011

FACT SHEET

Post-Approval: At INC Research, we understand that Post-Approval research is different from Pre-Approval development. To help you achieve success with your Post-Approval research initiatives, we focus on efficient and cost-effective delivery of studies and support programs designed to meet your needs for real-world data. We are a full-service provider, offering customized post-approval solutions across every clinical study, from study design consultations to the completion of the final study report. Unique Data Services and Data Management Tools INC Research provides a full range of data services and expertise to accelerate your clinical trials with greater accuracy and efficiency. As part of our Trusted Process, our tools for data management, electronic data capture (EDC) and biostatistics allow us to monitor data quality and study performance in real time and on an ongoing basis. Biostatistics INC Researchs Biostatistics Group provides our customers with sound statistical guidance and input at every phase of a products development. The group is expert in randomization methods, data collection, instrument design and data cleaning. The team has considerable experience with paper and electronic common technical document (CTD) submissions, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA), having submitted more than 25 New Drug Applications (NDA) and 90 Marketing Authorization Applications (MAA). Strategic and Regulatory Consulting The ability to determine the commercialization potential of a new drug is more important than ever. To help our customers succeed, INC Research offers several strategic and regulatory consulting service offerings: INC Researchs Strategic Consulting Group provides expertise that balances a global perspective with an understanding of important regional nuances to maximize the value of scientific knowledge, intellectual property and the content of your portfolio. INC Researchs AVOS Consulting offers independent perspectives on the future business environment for healthcare products and services. AVOS Consultings strategic, operational and financial analyses help life sciences companies compete successfully in an increasingly economically challenging and competitive environment. INC Researchs Regulatory Affairs team has extensive clinical trials expertise and offers experience in strategic submissions planning. With offices in the United States, European Union, Canada, China, India, and Latin America, our Regulatory Affairs staff is well versed with rapidly changing regulatory requirements across the globe. Our multifunctional global Regulatory Affairs team works closely with our regional technical experts to help guide strategies for product development in Phase I-IV clinical trials, product approval and post-approval studies.

www.incresearch.com

INC Research Fact Sheet | July 2011

FACT SHEET

Strategic Alliances INC Research is at the forefront of creating new models in which sponsors and CROs act as true partners with shared goals. We are uniquely positioned to build strategic alliance partnerships based on our expertise across the complete range of Phase I-IV clinical trials, expertise in pipeline management, registration strategies, compliance, due diligence and other aspects of drug development and commercialization. We work closely with customers to structure and manage successful alliances that share risks, increase costs savings, improve resource commitments and drive benefits in quality, consistency, efficiency and the bottom line. These benefits go far beyond what is possible in a tactical outsourcing relationship and are demonstrating the true value of strategic outsourcing. Functional Service Partnerships INC Research is among the pioneers of the FSP approach. This partnership model streamlines many of the repetitive tasks associated with the clinical trial process to increase time-saving and cost-saving synergies. The end result of implementing a FSP approach is greater predictability and more consistent delivery of services across all protocols. Today, INC Researchs FSP model touches more than 150 protocols every day. Innovating Drug Development as the Next-Generation CRO Faced with continued financial and competitive pressures, biopharmaceutical companies are moving beyond traditional outsourcing relationships and exploring new types of strategic partnerships designed to deliver greater benefits throughout the product development lifecycle. INC Research is uniquely positioned to deliver in the next generation of strategic partnerships and is driving change in the outsourcing industry with new approaches designed to improve the overall quality and efficiency of drug development. We are innovating new clinical research techniques, refining best practices and implementing the latest technologies to help our customers succeed and bring their products to market faster. We often are among the first to spot new trends in pharmaceutical research, develop new tools and build expertise in areas of interest to our customers. For example, we have been at the forefront of adaptive clinical trial design and building forward-thinking strategic alliances based on new risksharing and incentive structures. We believe these innovations and the innovations we are currently developing and will develop help our customers effectively address the growing list of constituencies they work with, from regulatory bodies and policymakers to payors and patients.

www.incresearch.com

INC Research Fact Sheet | July 2011

FACT SHEET

The Trusted Process Trust is the key for any long-lasting relationship and, since 2006, INC Research has conducted Phase I-IV trials based on our proprietary Trusted Process, a proven, metrics-driven, process-oriented methodology that ensures consistent delivery of the highest quality results to our customers. The Trusted Process reduces risk and ensures reliability and predictability by standardizing the operational aspects of a trial and maintaining quality controls at every phase of the clinical The result is substantially reduced operational risk and variability and faster cycle times. The Trusted Process is not static. INC Research is constantly evolving the process based on feedback from our customers, the availability of new informatics tools, and the changing realities of the industry. The Trusted Process turns customers into repeat customers because it delivers predictable, dependable outcomes. Ultimately, the Trusted Process helps our people help yours by focusing on the delivery of high-quality clinical trial results. Management Team The executive leadership includes: David Gill, Jamie Macdonald, Neil MacAllister, Executive Vice President, Corporate and Business Development, INC Research and President, AVOS Consulting Mark Roseman, DSc, Executive Vice President, Business Development and Marketing Your Trusted Partner The biopharmaceutical ecosystem is rapidly undergoing profound and systematic changes. With our expanded scale and depth of therapeutic capabilities, improved global reach and economies of scale, and focus on innovation and quality delivery through the Trusted Process, INC Research is uniquely positioned to enter into strategic alliances with biopharmaceutical companies, small and large. We look forward to becoming your Trusted Partner, helping you deliver the next generation of life-saving medicines.

www.incresearch.com

INC Research Fact Sheet | July 2011